<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166321</url>
  </required_header>
  <id_info>
    <org_study_id>MARCIE</org_study_id>
    <secondary_id>2009-016683-36</secondary_id>
    <nct_id>NCT01166321</nct_id>
  </id_info>
  <brief_title>Carbon Ion Radiotherapy for Atypical Meningiomas</brief_title>
  <acronym>MARCIE</acronym>
  <official_title>Treatment of Patients With Atypical Meningiomas Simpson Grade 4 and 5 With a Carbon Ion Boost in Combination With Postoperative Photon Radiotherapy: A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical&#xD;
      resection. With this approach, local control ranges between 50 and 70%, depending on&#xD;
      resection status. A series or smaller studies has shown that postoperative radiotherapy in&#xD;
      this patient population can increase progression-free survival, which translates into&#xD;
      increased overall survival. However, meningiomas are known to be radioresistant tumors, and&#xD;
      radiation doses of 60 Gy or higher have been shown to be necessary for tumor control.&#xD;
&#xD;
      Carbon ions offer physical and biological characteristics. Due to their inverted dose profile&#xD;
      and the high local dose deposition within the Bragg peak precise dose application and sparing&#xD;
      of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an&#xD;
      increased relative biological effectiveness (RBE), which can be calculated between 2 and 5&#xD;
      depending on the cell line as well as the endpoint analyzed.&#xD;
&#xD;
      First data obtained within the Phase I/II trial performed at GSI in Darmstadt on carbon ion&#xD;
      radiotherapy for patients with high-risk meningiomas has shown safety, and treatment results&#xD;
      are promising.&#xD;
&#xD;
      Therefore, in the current Phase II-MARCIE-Study a carbon ion boost will be applied to the&#xD;
      macroscopic tumor (gross tumor volume, GTV) in conjunction with photon radiotherapy to the&#xD;
      clinical target volume (CTV) in patients with atypical meningiomas after incomplete resection&#xD;
      or biopsy.&#xD;
&#xD;
      Primary endpoint is progression-free survival rate, secondary endpoints are overall survival,&#xD;
      safety and toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Progression-free survival at 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Overall Survival at 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Meningioma</condition>
  <arm_group>
    <arm_group_label>Carbon Ion Radiotherapy Boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carbon Ion Boost to the Macroscopic Tumor visible on contrast-enhanced MR-Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon Ion Radiotherapy</intervention_name>
    <description>Carbon Ion Boost 18 Gy E in single Fractions of 3 Gy E</description>
    <arm_group_label>Carbon Ion Radiotherapy Boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed atypical meningioma&#xD;
&#xD;
          -  macroscopic tumor after biopsy or subtotal resection&#xD;
&#xD;
          -  Simpson Grade 4 or 5&#xD;
&#xD;
          -  prior photon radiotherapy to the clinical target volume (CTV) of 48-52 Gy&#xD;
&#xD;
          -  beginning of study treatment no later than 12 weeks after surgery&#xD;
&#xD;
          -  age ≥ 18 years of age&#xD;
&#xD;
          -  Karnofsky Performance Score ≥ 60&#xD;
&#xD;
          -  For women with childbearing potential, adequate contraception&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of the clinical&#xD;
             trial&#xD;
&#xD;
          -  Written informed consent (must be available before enrolment in the trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal of the patients to take part in the study&#xD;
&#xD;
          -  previous radiotherapy of the brain&#xD;
&#xD;
          -  optic nerve sheath meningioma (ONSM)&#xD;
&#xD;
          -  time interval of &gt; 12 weeks after primary diagnosis (neurosurgical intervention) and&#xD;
             beginning of study treatment&#xD;
&#xD;
          -  Patients who have not yet recovered from acute toxicities of prior therapies&#xD;
&#xD;
          -  Known carcinoma &lt; 5 years ago (excluding Carcinoma in situ of the cervix, basal cell&#xD;
             carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment&#xD;
             interfering with study therapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Participation in another clinical study or observation period of competing trials,&#xD;
             respectively&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jürgen Debus, MD PhD</last_name>
    <phone>+49-6221-56-</phone>
    <phone_ext>8201</phone_ext>
    <email>juergen.debus@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hopsital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Debus, MD PhD</last_name>
      <phone>+49 6221 56</phone>
      <phone_ext>34093</phone_ext>
      <email>juergen.debus@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>July 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2010</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Prof. Dr. Dr. Jürgen Debus</investigator_title>
  </responsible_party>
  <keyword>Atypical Meningioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

